In keeping with that CXCL8 and ROS impact cancer progression and T cell survival, respectively (92, 93), and that T cell expansion capability is a predictor of successful clinical expansion (94), selection of T cell subsets ahead of CAR T cell engineering could be a strategy to move the field forward (Figure 2). The gene discussed is CXCL8; the disease is cancer.